Subscribe
tibor-duris-shutterstock-com-pills-
Tibor Duris / Shutterstock.com
5 January 2017Americas

Par Pharmaceutical in pre-emptive strike to protect Latuda generic

Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda (lurasidone hydrochloride).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Japanese firm acquires US drugmaker after increasing offer
25 October 2022   The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Americas
Sumitomo sues over antipsychotic drug
14 February 2018   Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025

More on this story

Big Pharma
Japanese firm acquires US drugmaker after increasing offer
25 October 2022   The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Americas
Sumitomo sues over antipsychotic drug
14 February 2018   Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

More on this story

Big Pharma
Japanese firm acquires US drugmaker after increasing offer
25 October 2022   The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Americas
Sumitomo sues over antipsychotic drug
14 February 2018   Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress